Amgen Price Target Increased to $149.00 by Analysts at Deutsche Bank (AMGN)
Deutsche Bank hoisted their price objective on shares of Amgen (NASDAQ:AMGN) from $144.00 to $149.00 in a research note issued on Friday. The firm currently has a “buy” rating on the stock. Deutsche Bank’s target price points to a potential upside of 29.13% from the stock’s previous close.
Shares of Amgen (NASDAQ:AMGN) traded up 2.09% during mid-day trading on Friday, hitting $117.7999. The stock had a trading volume of 1,884,305 shares. Amgen has a one year low of $103.31 and a one year high of $128.96. The stock’s 50-day moving average is $118.1 and its 200-day moving average is $118.4. The company has a market cap of $89.177 billion and a price-to-earnings ratio of 18.73.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, April 22nd. The company reported $1.87 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.94 by $0.07. The company had revenue of $4.52 billion for the quarter, compared to the consensus estimate of $4.76 billion. During the same quarter in the prior year, the company posted $1.96 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis. Analysts expect that Amgen will post $8.09 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Amgen in a research note on Tuesday, June 10th. They now have a $140.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Amgen from an “outperform” rating to a “neutral” rating in a research note on Tuesday, May 6th. They now have a $119.00 price target on the stock. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Amgen has an average rating of “Buy” and a consensus target price of $133.44.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.